Jefferies raises AstraZeneca target to 18,000p as analysts flip view on delayed cancer trialProactive Investors • 03/06/26
Baron International Growth Fund Q4 2025: Contributors, Detractors, And TradesSeeking Alpha • 02/27/26
AstraZeneca has 'sector leading replacement power' to cope with 2030 patent cliffProactive Investors • 02/26/26
Impax International Sustainable Economy Fund Q4 2025 Contributors And DetractorsSeeking Alpha • 02/18/26
Shore Capital downgrades AstraZeneca as R&D spending dampens earnings trajectoryProactive Investors • 02/13/26
Citi maintains 'buy' on AstraZeneca with £170 target, cites sector-best pipelineProactive Investors • 02/11/26
AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the USBusiness Wire • 02/11/26
AZN Q4 Earnings Miss Estimates, Stock Up on Robust 2026 Growth OutlookZacks Investment Research • 02/10/26
Here's What Key Metrics Tell Us About Astrazeneca (AZN) Q4 EarningsZacks Investment Research • 02/10/26
AstraZeneca Leans On Its Cancer Division For A Fourth-Quarter BeatInvestors Business Daily • 02/10/26
AstraZeneca lifts earnings as pipeline delivery and global expansion underpin growthProactive Investors • 02/10/26